LabCorp to Offer a New Companion Diagnostic for Melanoma

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a new FDA-approved diagnostic for melanoma patients. The drug Zelboraf TM and the cobas(R) 4800 BRAF V600 Mutation Test companion

Laboratory Corporation of America(R) Holdings Announces Results of Offer to Purchase Its Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the results of its offer (the "Offer") to purchase its Zero Coupon Convertible Subordinated Notes due 2021 (the "Notes") for cash.

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on October 7, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common

LabCorp Extends Agreement with UnitedHealthcare

BURLINGTON, N.C., Sep 08, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that it has extended the term of its agreement with UnitedHealthcare Insurance Company (UnitedHealthcare), an affiliate of UnitedHealth Group Incorporated

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch Global Healthcare Conference

BURLINGTON, N.C., Sep 06, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch Global Healthcare Conference in London,

LabCorp Introduces HCV Resistance Testing through Monogram Biosciences with the Launch of HCV GenoSure(R) NS3/4A

BURLINGTON, N.C., Aug 25, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a nucleic acid sequencing assay that reports NS3 and NS4A mutations and NS3 associated resistance to the recently approved

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C., Aug 15, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on September 9, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common

Laboratory Corporation of America(R) Holdings Announces Commencement of Offer to Purchase Its Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Aug 11, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) ("LabCorp") announced today that it is notifying holders of its Zero Coupon Convertible Subordinated Notes due 2021 (the "Notes") that they have the right, pursuant to the terms of the Notes,

LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute to Offer Specialized Biomarker and Assay Development Services

BURLINGTON, N.C., Aug 10, 2011 (BUSINESS WIRE) -- Esoterix Clinical Trials Services, a division of Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH), today announced a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access

Laboratory Corporation of America(R) Holdings Announces Second Quarter 2011 Results

Strong Volume and Revenue Growth Drives Adjusted EPS Excluding Amortization of $1.64 BURLINGTON, N.C., Jul 21, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced results for the quarter ended June 30, 2011.